AstraZeneca submitted a request for the FDA on Wednesday to approve a self-administered nasal flu vaccine for people ages two to 49 years old. The vaccine, FluMist, would become the first at-home vaccine that would allow anyone 18 years of age and older to administer it to themselves and those underage.
